Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review

Elyan, B. M.P., Rankin, S., Jones, R. , Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)

[img] Text
296462.pdf - Published Version
Available under License Creative Commons Attribution.

544kB

Abstract

No abstract available.

Item Type:Articles (Letter)
Additional Information:This work was in part funded by a Chief Scientist Office Lectureship (number PCL/20/10) to J.S.L.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Lang, Professor Ninian and Mark, Professor Patrick and Elyan, Dr Benjamin and Lees, Jennifer and Rankin, Dr Stephen and Jones, Professor Robert
Authors: Elyan, B. M.P., Rankin, S., Jones, R., Lang, N. N., Mark, P. B., and Lees, J. S.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Kidney Medicine
Publisher:Elsevier
ISSN:2590-0595
ISSN (Online):2590-0595
Published Online:16 May 2023
Copyright Holders:Copyright © 2023 Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
First Published:First published in Kidney Medicine 5(7):100672
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record